Leerink Partners

Bruker Corporation to Present at Investor Conferences

Retrieved on: 
Monday, February 25, 2019

BILLERICA, Mass., Feb. 25, 2019 /PRNewswire/ --Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:

Key Points: 
  • BILLERICA, Mass., Feb. 25, 2019 /PRNewswire/ --Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:
    8th Annual SVB Leerink Healthcare Conference, New York, NY
    Cowen 39th Annual Health Care Conference, Boston, MA
    Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com .
  • Replays will be posted on the Bruker Corporation Investor Relations website after each event and will be available for 30 days following the presentation.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.
  • Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York.
  • A live webcast of Ironwoods presentation will be accessible through the Investors section of the companys website at www.ironwoodpharma.com .
  • A replay of the webcast will be available on Ironwoods website for 14 days following the conference.
  • Ironwood Pharmaceuticals (Nasdaq: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team.

Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET.

Key Points: 
  • Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET.
  • An audio webcast of the presentation will be available live.
  • You can access the webcast at: http://ir.alexion.com .
  • An archived version of the remarks will also be available through the Companys website for a limited time following the conference.

NuVasive To Present At 8th Annual Leerink Partners Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

SAN DIEGO, Feb. 21, 2019 /PRNewswire/ --NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will present at the 8th Annual Leerink Partners Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Thursday, Feb. 28, 2019 at 9 a.m.

Key Points: 
  • SAN DIEGO, Feb. 21, 2019 /PRNewswire/ --NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will present at the 8th Annual Leerink Partners Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Thursday, Feb. 28, 2019 at 9 a.m.
  • A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com .
  • A replay of the presentation will remain available on the website for 30 days after the applicable live webcast.
  • NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

BOULDER, Colo., Feb. 21, 2019 /PRNewswire/ --Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York.

Key Points: 
  • BOULDER, Colo., Feb. 21, 2019 /PRNewswire/ --Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York.
  • The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
  • Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.
  • BRAFTOVI and MEKTOVI are registered trademarks of Array BioPharma Inc. in the United States and various other countries.

Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

DUBLIN, Feb. 21, 2019 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:00 a.m.

Key Points: 
  • DUBLIN, Feb. 21, 2019 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:00 a.m.
  • A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com , under the Presentations & Events tab.
  • Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
  • THERAVANCE and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies.

Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

Retrieved on: 
Thursday, February 21, 2019

SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:30 AM EST.

Key Points: 
  • SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:30 AM EST.
  • The conference will take place February 27 March 1, 2019 at the Lotte New York Palace in New York City.
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST in New York, NY.

Key Points: 
  • Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST in New York, NY.
  • A live webcast of the presentation will be available on the investors section of the Companys website at www.verastem.com .
  • Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
  • Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkins lymphoma (iNHL).

Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m.

Key Points: 
  • Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m.
  • ET (10:30 a.m. PT) at the Lotte New York Palace in New York City.
  • Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic bladder cancer.
  • The companys antibody, vofatamab (formerly B-701), is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and other cancers.

Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 21, 2019

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.

Key Points: 
  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.
  • A live webcast of the presentation will be available on the Investors & Media section of Millendos website at http://investors.millendo.com .
  • A replay of the webcast will be archived on Millendos website for 30 days following the presentation.
  • Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient.